Don't have an account?
Learn More -or- Register Now
Are you an expert on what it takes to generate income once your regular paycheck stops? Take this quick test to find out.
Take the TestSpryng is a new crowdfunding tool for college savings where you create a personalized profile and share it with friends and family.
Learn moreOpen popular accounts online:
Don't have an account?
Learn More -or- Register Now
Change is happening rapidly, active management helps us identify and capitalize on significant inflection points.
Matthew J. Moberg Senior Vice President, Portfolio Manager, Franklin Equity Group
I looked at my iPhone after a run in Central Park. Good. 57 minutes, and for 33 my heart rate was over 160 beats per minute. I had achieved my daily fitness goal. I pressed “save” on my app so I can monitor my fitness levels over time. I had a small headache and had just bought a blood sugar monitor, so I checked my app and saw that my blood sugar was normal. Also good. My headache was probably from thirst, and I know that sugar headaches take me much longer to recover from than dehydration headaches. My hotel was downtown, so I grabbed an Uber. Getting into the car, my phone alerted me I could check in to tomorrow’s flight to San Francisco. The flight was on time. I checked in. In the cab, I watched a few stories from friends in social feeds. I was reminded to text my friend to see what time we’d have dinner. I made a quick reservation at a Mexican restaurant in SoHo recommended by a location-based app. Traffic wasn’t great, so I absently looked at e-mail and saw that the maker of the cement bookends I really liked was willing to make me three more. I bought them. Arriving at the hotel, I quickly hopped out of my Uber, having already paid the driver through the app. I recalled reading that the average US adult spends 5 hours on their phone. I thought that sounded high, but wondered if it were true…
Over the last decade, smartphones have revolutionized our lives in ways that go well beyond mere audio communication. In addition to Facetime video chats, texting and emailing, billions of people globally use smartphones to shop online, check the weather, hail taxis, navigate, monitor their health, invest, play games, date, find friends, watch movies, listen to music, take pictures and participate in social media.
This is quite remarkable when you think about it—an innovation impacting the world so pervasively that it has transformed our lives in such a short time. Recall it was just thirteen years ago that Steve Jobs—wearing his iconic black turtleneck on the stage of the Moscone Convention Center—introduced the world to the smartphone.
Smartphones are only one example of the many new products and technologies exploding into the economy in recent years. We’ve seen significant breakthroughs in biotechnology, robotics, artificial intelligence, genomics, wireless data speeds, 3D printing, autonomous vehicles, cloud computing, e-commerce and more. Innovation is everywhere. As investment managers we’ve witnessed many concepts surge in popularity, and we’ve learned from many that have failed. Industry and technology continue to evolve, creating a rich backdrop for investors.
Download the PDF to continue reading the article.
All investments involve risks, including possible loss of principal. Stock prices fluctuate, sometimes rapidly and dramatically, due to factors affecting individual companies, particular industries or sectors, or general market conditions. Special risks are associated with foreign investing, including currency fluctuations, economic instability and political developments. Investments in emerging markets involve heightened risks related to the same factors, in addition to those associated with these markets’ smaller size and lesser liquidity. Investments in fast-growing industries like the technology sector (which historically has been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments. The companies and case studies shown herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton Investments. The opinions are intended solely to provide insight into how securities are analyzed. The information provided is not a recommendation or individual investment advice for any particular security, strategy, or investment product and is not an indication of the trading intent of any Franklin Templeton managed portfolio. This is not a complete analysis of every material fact regarding any industry, security or investment and should not be viewed as an investment recommendation. This is intended to provide insight into the portfolio selection and research process. Factual statements are taken from sources considered reliable but have not been independently verified for completeness or accuracy. These opinions may not be relied upon as investment advice or as an offer for any particular security. Past performance does not guarantee future results.
This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice.
The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market. All investments involve risks, including possible loss of principal.
Data from third party sources may have been used in the preparation of this material and Franklin Templeton ("FT") has not independently verified, validated or audited such data. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments opinions and analyses in the material is at the sole discretion of the user.
Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.
Issued in the U.S. by Franklin Templeton Distributors, Inc., One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com - Franklin Templeton Distributors, Inc. is the principal distributor of Franklin Templeton U.S. registered products, which are not FDIC insured; may lose value; and are not bank guaranteed and are available only in jurisdictions where an offer or solicitation of such products is permitted under applicable laws and regulation.
You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.
Franklin Templeton Distributors, Inc.
This website is for US residents.
This website is for US residents.
Copyright © 2021 Franklin Templeton. All Rights Reserved.
There are literature items in your cart. If you sign out, all items will be removed.
Click "Stay Signed In" to continue your session and keep items in your cart.
Otherwise, click Sign out to end your session and empty your cart.
You can compare a maximum of 4 funds.
Money funds and liquidated funds cannot be added to comparison.
Quarterly commentary discussing fund performance. View more details
Client Use: | (FINRA Letter) |
---|---|
Literature Code: | |
Format: | () |
Publication Date: | |
Next Update: |